NHC-affiliated · Century-old renowned hospital
Established
1907
Beds
2,500+
Annual Volume
70,000+
Shanghai
National benchmark for hematologic oncology; the world-renowned APL cure protocol was born here, and China’s first domestically built proton system is installed here.
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, founded in 1907, is world-renowned for hematology — Academician Wang Zhenyi’s differentiation therapy for acute promyelocytic leukemia (APL) made it the first curable acute leukemia, earning the highest international recognition in hematology.
Its hematology department is the National Clinical Research Center for Hematologic Diseases, with CAR-T therapy and stem-cell transplantation volumes among the highest nationally; the first domestically developed proton therapy system is also installed at Ruijin.
01Global authority in hematologic malignancies
Birthplace of APL differentiation therapy; leukemia, lymphoma and myeloma programs rank in the national first tier in both volume and research.
02Leading CAR-T and transplant volumes
Annual stem-cell transplant and CAR-T volumes rank among the highest nationally, with extensive salvage-therapy experience in relapsed/refractory disease.
03Domestic proton therapy system
The first domestically developed proton system entered service here with a more optimized cost structure, offering a new high-precision option for solid tumors.
In 2021, Ruijin delivered China’s first commercial CAR-T (axicabtagene ciloleucel) treatment for diffuse large B-cell lymphoma; the patient achieved complete remission, marking the start of commercial cell therapy in China.
The team of Wang Zhenyi, Chen Zhu and Chen Guoqiang pioneered the “Shanghai regimen” of all-trans retinoic acid plus arsenic for acute promyelocytic leukemia, raising the cure rate above 90% — a model of cancer therapy.